Protocol Ledger

NCT05444257 · Phase III · ACTIVE NOT RECRUITING

A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy

Interventional Phase III clinical trial protocol NCT05444257 sponsored by Vertex Pharmaceuticals in Respiratory and Pulmonary, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-11-08 Enrollment: 822 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05444257
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)822 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05444257
Protocol FieldVerified Registry Value
NCT IdentifierNCT05444257
Consolidated Lead SponsorVertex Pharmaceuticals
Therapeutic Condition CohortRespiratory and Pulmonary
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment822 participants (ACTUAL)
Registered Start Date2022-11-08
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Vertex Pharmaceuticals across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Respiratory and Pulmonary Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI